Future Science Group celebrates 10 years of Immunotherapy
Future Science Group (FSG; London, UK) is celebrating the 10-year anniversary of the journal Immunotherapy with a two-part Special Focus Issue highlighting the latest key advances made in the field.
Since the launch of Immunotherapy in 2009, the field has undergone a very exciting decade and has evolved dramatically. Remarkable developments have led to a range of novel treatments for autoimmune diseases, allergies and cancer, amongst others. The emergence and advancement in the study and application of genetically engineered chimeric antigen receptor T cells and checkpoint inhibitors for the treatment of cancer have been particularly important areas of research.
In the last decade, Immunotherapy has strived to keep up with the incredible progress made in this exciting field and has continually showcased the latest groundbreaking advances across the whole research spectrum.
The two Special Focus Issues, both published in early 2019, aim to highlight and provide insight into the key topics and crucial areas of study in the field of immunotherapy. Compiled with help from members of the journal’s editorial board and regular contributors, these issues provide a broad representation of the field, detailing the past, present and future possibilities in the diagnosis and treatment of cancers, allergies and autoimmune diseases.
Mike Gregg, the Commissioning Editor of Immunotherapy (FSG, UK), opens each issue with a scene-setting Foreword, providing an overview of the wide variety of articles featured which include opinionated Editorials, Original Research and Reviews.
Gregg commented: “It has been an incredible first 10 years for Immunotherapy, during which, the journal has grown a reputation as a leader in the field. The Immunotherapy editorial department is excited to continue to build on this by publishing the latest research, discoveries and expert commentary and are looking forward to what the next 10 years will bring.’
Source: www.future-science-group.com/10-years-of-immunotherapy
View Parts I and II of the Special Focus Issue for free by clicking the links below:
Part I: www.futuremedicine.com/toc/imt/11/1
Part II: www.futuremedicine.com/toc/imt/11/2
Key papers from the Special Focus Issue:
The complicated effects of obesity on cancer and immunotherapy
